Think

AMAG Pharmaceuticals Uncertain on Future

Posted by Nick Buenaventura on Jan 18, 2017 11:47:24 AM

AMAG Pharmaceuticals (NASDAQ:AMAG) saw a sharp drop in its debt in the past week following the release of its actual results in sales. Although the pharma company saw its sales rise to a new record in this past year, investors are concerned as its top-selling drug, Makena, is set to lose its patent exclusivity in 2018. The maternal drug aid currently makes up 70% of AMAG's sales and with no defense to differentiate it from generics, investors are uncertain of how the company will be able to cope.

Read More

Topics: AMAG, Pharmaceuticals, Loans

Valeant Pharmaceuticals Takes Another Hit as Takeda Deal Falls Through

Posted by Nick Buenaventura on Dec 1, 2016 10:18:10 AM

Controversial Valeant Pharmaceuticals (NYSE: VRX) in the news again as the deal to sell their division of Salix to the Japenese company, Takeda (TYO: 4502), broke down. The disagreement to sell the gastrointestinal-drugs division of Valeant caused further turmoil in their bonds as they dropped over 2 cents following the announcement. The volatility is nothing new to the pharmaceutical company as just earlier this month they experienced a significant drop in prices when they severed ties with Philidor Rx Services, LLC

Read More

Topics: Pharmaceuticals, Valeant, Takeda, Salix, Philidor


Are you using AdvantageData?

AdvantageData is your fixed income solution for pricing, analytics, reports, and insight on approximately:

  • 529,400+ U.S. and international corporate bonds
  • Over 6,200+ CDS reference entities
  • Over 22,000+ syndicated loans
  • Over 100 equity markets worldwide
  • One platform 14 asset classes from debt to CDS to loans to mid-market
  • Used by top buy and sell-side firms worldwide

 

Subscribe to Email Updates

Recent Posts